Objectives: To evaluate the influence on mortality of empirical double-active combination antimicrobial therapy (DACT) compared with active monotherapy (AM) in septic shock patients.
Introduction
Empirical antimicrobial treatment is defined as therapy started in the absence of a definitive pathogen identification. Recent guidelines suggest double-active empirical combination therapy (i.e. using at least two antibiotics of different antimicrobial classes intended to cover the presumed pathogen) only for the initial management of septic shock (weak recommendation, low quality of evidence), while the routine use of combination therapy is not advised for other serious infections (including sepsis without shock and neutropenic sepsis). 1 Virtually no randomized clinical trials investigating empirical antimicrobial treatment in septic shock are available, and most data are derived from retrospective or observational studies. The evidence on the putative beneficial effect of empirical double-active therapy over monotherapy in patients with shock is essentially derived from a large propensity score (PS)-matched analysis 2 supported by a meta-analytic regression study 3 and data from a few additional observational series. 4, 5 However, other authors have been unable to find any positive influence of V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
combination therapy on survival in critically ill patients with Gramnegative bacteraemia and Pitt scores 4, 6 in patients with Pseudomonas aeruginosa bacteraemia and shock 7 or in patients with severe sepsis randomly assigned to receive meropenem alone or combined with moxifloxacin. 8 Therefore, while part of the rationale for using combination treatment is to provide broadspectrum coverage for different potential pathogens, limited and controversial data are available concerning the possible benefit of a strategy combining two or more active agents against the causative pathogen early in the course of septic shock. The aim of this study was to evaluate the potential benefits of active empirical combination therapy in patients with documented bacteraemia and septic shock.
Patients and methods

Study design, patients, variables and definitions
This was a retrospective study of patients admitted to Hospital Clinic, a 700 bed university hospital in Barcelona, Cataluña, Spain, presenting with septic shock and documented monomicrobial bacteraemia who received active empirical antimicrobial therapy. Patients admitted from 1 January 2010 to 31 December 2015 were included. In our centre, a dedicated team of infectious diseases physicians and microbiologists identifies and prospectively follows up all patients with bacteraemia until death or 30 days after diagnosis, whichever occurs first. From each patient, a set of selected demographic, clinical, biochemical, microbiological and antimicrobial treatment variables are collected and entered in a specific database. Information about treatment limitations or do not resuscitate orders was not recorded.
Samples for blood cultures were inoculated into aerobic and anaerobic vials and processed by the Bactec 9240 System (Becton-Dickinson), with an incubation period of 5 days.
As the data were obtained before the publication of the new Sepsis-3 guidelines, 9 shock was defined according to previous guidelines as hypotension persisting despite adequate fluid resuscitation. 10 Active empirical antibiotic therapy was defined as a treatment started within the first 24 h of the index blood cultures, having in vitro activity against the bacteria subsequently isolated and being administered at an appropriate dose by an adequate route. Empirical double-active combination therapy (DACT) was defined as therapy composed of at least two active antimicrobials with a different mechanism of action against the isolated pathogen. Empirical active monotherapy (AM) was defined as receiving only one active antimicrobial. Prior surgery or other invasive procedures, previous hospitalization, treatment with corticosteroids (20 mg of daily prednisone or equivalent) and prior antibiotic therapy refers to exposure within the month preceding the onset of bacteraemia. Time to positivity (TTP) of each positive vial in a given set of blood cultures as provided by the automatic blood culture processor was registered and the shortest one (if growth was detected in several bottles) was considered for the analysis. Acute kidney injury (AKI) and chronic kidney disease (CKD) were defined according to the KDIGO definitions. 11, 12 Alcoholism was defined as daily alcohol intake .100 g. The primary outcome was all-cause mortality at 7, 15 and 30 days from the onset of bacteraemia.
Ethics
The study was approved by the local ethics committee (HCB-2017-0200).
Statistical analysis
Baseline characteristics were compared using the v 2 test or Fisher's exact test for categorical variables and Wilcoxon's rank sum test for continuous variables. A univariate logistic regression analysis was carried out to explore factors associated with 7, 15 and 30 day all-cause mortality.
A PS was calculated after constructing a non-parsimonious logistic regression model taking the assigned therapy as the dependent variable. 13 Factors that could potentially affect the decision to use combination therapy were included as independent variables, hence microbiological and clinical variables temporally following the possible choice of combination therapy were excluded. Accordingly, the covariates introduced in the logistic regression model were age, sex, co-morbidities, prognosis of the underlying disease according to the McCabe criteria, 14 previous surgery or invasive procedures, treatment with corticosteroids, prior hospitalization, origin of bacteraemia (community-acquired, hospital-acquired, healthcare-associated), previous antibiotic therapy, source of infection, ICU stay at the time of bacteraemia, transfer to the ICU within the first 24 h of blood culture extraction, invasive mechanical ventilation (MV) at the time of bacteraemia, presence of fever, neutropenia (absolute neutrophil count of ,500 cells/mm 3 ), disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS) and septic metastases. The C-statistic of the constructed model discriminated reasonably well between the two groups (AUC " 0.78; 95% CI 0.74-0.82). The PS was used in two ways. Firstly, as a covariate in the multivariate analysis predicting 7, 15 and 30 day mortality in all included patients; secondly, to perform a propensitymatched analysis by matching each patient who received DACT with one receiving AM by the nearest neighbour technique using a calliper of width equal to 0.2 of the pooled standard deviation of the PS logit.
A multivariate model for predicting 7, 15 and 30 day mortality was subsequently built by subjecting variables with a univariate P value ,0.20 to a forward stepwise logistic regression procedure. Interactions between the assigned therapy group variable and other variables were explored. The variables defining the assigned therapy group and the PS were forced into all models where not already included. In order to further examine the potential effect of DACT in several predefined subgroups of interest, a multivariate model comprising the assigned therapy group and the PS was built for patients with neutropenia, haematological malignancy, unknown source of infection, pulmonary source of infection, TTP ,7.5 h (i.e. lower than the 25th percentile of our cohort), P. aeruginosa bacteraemia and for patients receiving an active b-lactam. Finally, univariate and multivariate conditional logistic regression analysis was performed in the cohort of propensity-matched patients. Statistical analysis was carried out by using SPSS 20.0 (IBM SPSS, Chicago, IL, USA). 15 A two-tailed P value of ,0.05 was considered significant.
Results
Patient characteristics
Between January 2010 and December 2015, 5867 patients with positive blood cultures were identified. Among these, 882 presented with septic shock. Monomicrobial aetiology was documented in 741 patients, and 576 patients received an active empirical therapy (340 patients with empirical AM and 236 patients with empirical DACT). Baseline characteristics of the entire cohort are described in Tables 1 and 2 .
Several differences between the two groups were evident at baseline. Patients receiving DACT were younger, were being treated with corticosteroids more often and were more likely to have a non-fatal underlying disease, a haematological malignancy, neutropenia, an unknown and pulmonary source of infection and Staphylococcus aureus and Streptococcus pneumoniae bacteraemia. Conversely, patients who received AM were more likely to have solid organ malignancies, prior surgery, an intraabdominal, biliary or urinary source of infection and Escherichia coli and enterococci as causative microorganisms. Finally, most of the Ripa et al. Crude mortality in the DACT group versus the AM group was not significantly different at days 7 (17.4% versus 22.1%, P " 0.172), 15 (22.0% versus 27.4%, P " 0.172) and 30 (30.1% versus 31.8%, P " 0.714).
Factors associated with 7, 15 and 30 day all-cause mortality
In univariate analysis (Table 3) , mortality at 7 days was associated with older age, a rapidly or ultimately fatal underlying disease (according to the McCabe score), invasive MV at onset of bacteraemia and need for invasive MV after bacteraemia onset, DIC, ARDS, a shorter TTP and an unknown, pulmonary or skin and soft-tissue source of infection. Factors associated with a better outcome were the presence of fever, transfer to the ICU within the first 24 h after bacteraemia onset, a urinary or vascular catheter source of infection and empirical treatment with a glycopeptide. Multivariate logistic regression analysis including the PS for receiving DACT selected older age, an ultimately/rapidly fatal underlying disease, absence of fever, invasive MV at onset of bacteraemia and need for invasive MV after bacteraemia onset, DIC, sources other than the urinary tract or vascular catheter and a TTP ,10.5 h as independent predictors of death. The association of DACT with a better outcome was borderline non-significant (OR 0.61, 95% CI 0.36-1.06, P " 0.08).
Multivariate analyses to evaluate factors associated with 15 and 30 day mortality are shown in Table 4 . Empirical DACT was not associated with a better outcome. Interestingly, while factors associated with 7 and 15 day all-cause mortality were comparable, predictors at 30 days were quite different. Notably, besides a urinary source, other infection sources were not significantly associated with mortality. Moreover, TTP ceased to be a significant prognostic factor, while selected baseline patient characteristics such as previous treatment with b-lactam/b-lactamase inhibitors, cirrhosis or CKD, which did not influence 7 and 15 day mortality, were significantly associated with a worse prognosis at 30 days.
PS-matched analysis
A cohort of 178 matched pairs of patients could be assembled by the PS-matching procedure and their baseline characteristics are shown in Tables 1 and 2 . No significant differences in baseline characteristics were evident between the two groups. As matching was done using the variables available to the clinician at the time of treatment choice, some differences in terms of isolated pathogen remained. Patients receiving empirical DACT were more likely to have S. pneumoniae as causative microorganism, while Enterococcus spp. and CoNS were more frequently isolated in patients receiving empirical AM. As expected from the propensitymatching procedure, differences in the empirical antimicrobial regimens were also present, as patients receiving DACT were more likely to receive carbapenems, aminoglycosides, fluoroquinolones and colistin. The conditional logistic regression analysis taking all these factors into account did not show a significant association of empirical DACT with mortality at 7 (OR 1.04; 95% CI 0.36-3.02, P " 0.9), 15 (OR 0.93; 95% CI 0.35-2.45, P " 0.8) and 30 days (OR 1.23; 95% CI 0.48-3.12, P " 0.6). Empirical double-active combination therapy in septic shock JAC Influence on mortality of empirical DACT in specific subsets of patients Multivariate models comprising the assigned therapy group and the PS were performed to explore the influence of empirical DACT in patients with neutropenia, haematological malignancy, unknown source of infection, pulmonary source of infection, TTP of blood cultures ,7.5 h and P. aeruginosa bacteraemia, and those receiving an active b-lactam (Table 5) .
In patients with neutropenia, DACT was independently associated with a better outcome at 15 and 30 days, while in patients with an underlying haematological malignancy no association between DACT and mortality was apparent. Moreover, no protective effect on mortality at any time point was evident when analysing patients with a pulmonary or unknown source of infection or in patients with a TTP ,7.5 h. Interestingly, when evaluating patients with P. aeruginosa infection, DACT was associated with lower 7 and 30 day mortality. Finally, we examined the subgroup of patients who received an active b-lactam as monotherapy compared with patients who received DACT comprising a b-lactam. The addition of a second active agent to a b-lactam was not associated with reduced mortality. Ripa et al.
Discussion
In this retrospective study, the effect of empirical DACT compared with AM in a cohort of 576 patients with documented monobacterial septic shock was analysed. At most, a borderline nonsignificant association of DACT with a better outcome was observed when evaluating 7 day mortality, although not even this could be confirmed in an additional PS-matched analysis. However, according to a subgroup analysis of the entire cohort, a lower mortality risk in patients with P. aeruginosa infection and in those with neutropenia cannot be dismissed. The potential advantage of DACT is mainly related to the possibility of a synergistic effect of two molecules with different mechanisms of action. This synergism may potentially translate into faster pathogen clearance, thus reducing the bacterial burden during the early phases of septic shock. 16 However, in spite of the biological plausibility of this hypothesis, strong evidence supporting a beneficial effect of DACT is still lacking. A recent meta-analysis evaluating patients with severe sepsis admitted to the ICU 17 failed to show differences between empirical mono-and combination antimicrobial therapy in terms of mortality and other secondary outcomes. Previously, other meta-analyses focusing on sepsis in either immunocompetent patients, 18, 19 neutropenic subjects 20, 21 or both, 22 and in patients with Gram-negative bacteraemia, 23 were unable to show a beneficial effect of combination antimicrobial therapy. Although these meta-analyses assessed mostly trials evaluating empirical treatment, studies testing semi-empirical and definitive therapy were also included, and none focused on patients with septic shock or specifically addressed whether both components of combination therapy were active. Meanwhile, a large PS-matched study 3 and a meta-analytical/meta-regression study 4 highlighted improved survival in patients with septic shock who received empirical DACT. The latter also suggested that the beneficial effect of combination therapy was restricted to the subset of patients with a basal higher risk of mortality (.25%), being in fact detrimental when the mortality risk was 15%. These observations have never been replicated, although two retrospective cohort studies using multivariate analysis found a decreased mortality risk associated with combination therapy in patients with severe sepsis or septic shock. 5, 6 Our retrospective analysis evaluated patients with septic shock regardless of causative pathogens, underlying immune status and type of combination therapy and Empirical double-active combination therapy in septic shock JAC used a PS for adjusting and matching patients, yielding results that are coherent with what was described in the above-mentioned meta-analyses. In the present study, although a borderline nonsignificant association of DACT with a better 7 day survival was noted after adjusting for other confounders (including the PS), this could not be confirmed in the matched analysis, which clearly led the association of DACT with 7 day mortality towards the null hypothesis. Nevertheless, in order to deal with heterogeneity, we further explored the effect of combination therapy in specific subsets of patients. Although DACT had no influence on mortality in patients with haematological malignancies, unknown and pulmonary source of infection and those with a short TTP, a protective influence on mortality was evident in patients with P. aeruginosa infection and in neutropenic patients. Even though a previous meta-analysis 23 showed a lower mortality in patients with P. aeruginosa bacteraemia treated with active combination therapy, more recent systematic reviews 24, 25 did not find evidence for a reduced mortality in this population, and the overall effect observed in the first of the above-mentioned meta-analysis has been criticized because several of the assessed studies included a significant proportion of patients with single aminoglycoside in the monotherapy arm. 26 Moreover, none of the additional observational studies on P. aeruginosa bacteraemia has been able to demonstrate an overall beneficial effect of empirical combination therapy on mortality. 8, [27] [28] [29] [30] However, no studies have focused specifically on patients with septic shock due to P. aeruginosa, although in one of them 8 a subgroup analysis of 115 patients with shock did not show any beneficial effect of DACT compared with AM. Our findings have to be taken with caution as only 61 episodes of septic shock were due to P. aeruginosa.
The role of empirical combination therapy in neutropenic patients is also being debated. Most patients with febrile neutropenia lack a microbiological diagnosis, 31 making it difficult to clearly evaluate the effect of an empirical treatment employing two active molecules. Two meta-analyses by the same group 20, 21 did not find any advantage in active combination therapy, either overall or Ripa et al.
specifically in the 71 participants with documented P. aeruginosa infection. However, two prior observational studies have reported a better survival in neutropenic patients with bacteraemia due to Gram-negative microorganisms 5 or P. aeruginosa 28 receiving combination therapy than in those receiving monotherapy.
In the present study, several factors were associated with mortality. As expected, older age, worse prognosis of the underlying disease according to the McCabe criteria and a more severe baseline clinical picture (such as DIC and a need for MV) were associated with higher 7, 15 and 30 day mortality. [32] [33] [34] Interestingly, the presence of fever was associated with a better outcome, as has been reported by others. [35] [36] [37] The physiopathological plausibility of this finding may lie in the beneficial effects of fever on host immunity and the activity of some antimicrobials as well as its detrimental effect on the replication of some pathogens. 38 Early transfer to an ICU was also associated with a better outcome at all time points. This agrees with prior observations showing that for patients with septic shock, delaying ICU admission 39, 40 or being admitted to less-experienced units 34 was associated with higher mortality. Although some authors have not found differences in prognosis according to the infection site in patients with severe sepsis, 41 in the present study and as previously described, 29, 42 catheterrelated and urinary tract infections were associated with a better outcome, probably due to the fact that effective source control may be pursued in these patients. Notably, a shorter TTP of blood cultures was associated with a higher early mortality. The association of TTP with clinical characteristics, aetiology and source of infection has been described previously. 43 Moreover, others have already suggested that TTP may be a predictor of mortality in patients with bacteraemia due to Gram-negative bacilli [44] [45] [46] [47] [48] and MSSA. 49 To our knowledge, this is the first report that shows that TTP is an independent predictor of mortality in septic shock, regardless of infectious aetiology and source. This finding probably indicates a higher microbial inoculum, which may impair both the patient's and the antimicrobial agent's ability to clear the infection in the earliest stages of septic shock, regardless of whether DACT or AM is administered. The lack of association of TTP with 30 day mortality further supports this hypothesis, suggesting that in patients who survived after the early phases of infection, the initial bacterial burden is no longer associated with mortality. Finally, 30 day mortality was associated with cirrhosis and CKD. The fact that these comorbidities were not independently associated with early mortality suggests a greater influence of the acute events triggered by infection in determining an early fatal outcome while baseline comorbidities have a more important prognostic role at later times.
Our study has several limitations. Owing to its retrospective nature, confounding factors that were not collected or analysed may have had an impact on mortality. Nevertheless, by applying a multivariate analysis including a PS for receiving empirical DACT we tried to compensate for possible assignment biases. Data that could give a better description of the severity of the patients, such as APACHE or SOFA score, were not included in the analyses as they were not available for the majority of patients. Moreover, time of administration of the first dose of antibiotic was not available for all of them. These factors may indeed be related to early in-hospital mortality. However, given the high number of variables related to known comorbidities and current clinical condition (such as MV, ICU stay or early transfer to ICU), we believe that patients were appropriately classified in terms of clinical severity. Finally, the study being from a single centre and the limited number of patients included may preclude a generalization of results. In particular, the relatively small series of patients with neutropenia and with P. aeruginosa infection was indeed too small to draw definite conclusions. Future studies aimed at assessing the potential beneficial effect of empirical combination therapy in these specific subgroups are needed to better evaluate this strategy.
In conclusion, the present study has not shown consistent evidence of a beneficial influence of empirical DACT over empirical AM on 7, 15 or 30 day mortality in patients with bacteraemia and septic shock. However, a significant protective effect on mortality at some time points within the 30 day period after bacteraemia onset in patients with neutropenia or those with infection due to P. aeruginosa is worthy of further study.
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